Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study
2007

Study on Autoantibodies in Rheumatoid Arthritis Treatment

Sample size: 6 publication Evidence: moderate

Author Information

Author(s): Teng YK Onno, Verburg Robert J, Verpoort Kirsten N, Diepenhorst Gwendolyn MP, Bajema Ingeborg M, van Tol Maarten JD, Jol-van der Zijde Els CM, Toes Rene EM, Huizinga Tom WJ, van Laar Jacob M

Primary Institution: Leiden University Medical Center

Hypothesis

The study investigates the relationship between autoantibody levels and clinical responses in refractory rheumatoid arthritis patients treated with immunoablative therapy.

Conclusion

The study found that lower avidity anti-cyclic citrullinated protein autoantibodies are associated with better clinical responses to immunoablative therapy in rheumatoid arthritis patients.

Supporting Evidence

  • Three patients showed significant reductions in ACPA-IgG levels after therapy.
  • Clinical responders had lower avidity ACPA-IgG and higher inflammation scores.
  • Relapses were preceded by rising levels of low avidity ACPA-IgG.

Takeaway

Doctors looked at how certain antibodies in the blood of arthritis patients changed after treatment, and found that those with lower levels of a specific antibody did better.

Methodology

The study involved six patients with refractory rheumatoid arthritis who were treated with high-dose chemotherapy and autologous stem cell transplantation, with extensive monitoring of autoantibody levels and clinical responses.

Limitations

The study is limited by the small sample size and the variability in individual patient responses.

Participant Demographics

All patients had a median disease duration of 12 years and were seropositive for rheumatoid factor and anti-cyclic citrullinated protein antibodies.

Statistical Information

P-Value

0.05

Statistical Significance

p=0.05

Digital Object Identifier (DOI)

10.1186/ar2309

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication